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LCAT deficiency and atherosclerosis 
GRAPHICAL ABSTRACT 
Highlights: 
 Conflicting results over the role of LCAT in preclinical atherosclerosis
 Dutch and Italian cohorts were combined in the largest available cohort of
LCAT mutation carriers to date
 HDL-c levels were reduced by 42% in both carriers of FED as well as FLD
mutations
 LDL-c levels were decreased by 20% in FLD vs FED and controls
 Preclinical atherosclerosis (intima media thickness) was reduced in FLD vs
FED and controls and increased in FED carriers
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ABSTRACT 
BACKGROUND: 
Lecithin:cholesterol acyltransferase (LCAT) is one of the main factors needed 
for the de novo synthesis of high-density lipoprotein (HDL), however, its role 
in atherosclerosis is unclear despite 50 years of research. The impact of 
genetically reduced LCAT function on preclinical atherosclerosis has been 
previously assessed in two major cross-sectional studies which rendered fully 
opposite results: while heterozygous carriers of LCAT mutations mostly 
diagnosed with Fish-eye Disease (FED) showed increased atherosclerosis, 
carriers of LCAT mutations mostly diagnosed with familial LCAT deficiency 
(FLD) instead presented with reduced atherosclerosis. The current study 
readdresses the question whether LCAT is pro or antiatherogenic. 
METHODS AND RESULTS: 
Thirty-seven FLD subjects, 53 FED subjects, and 280 controls were studied. 
Compared to controls, total cholesterol levels were reduced by 21 and 11% in 
FLD and FED mutation carriers, respectively. The impact of mutations on HDL 
cholesterol levels was identical in both groups (-42%). FLD subjects, however, 
displayed a mean significant 20% decrease in LDL-cholesterol levels compared 
with FED and controls. Remarkably, the FLD group presented overall with 
significantly lower carotid intima-media thickness (IMT) compared to the FED 
group and controls. In sharp contrast, a significant increase in the common 
carotid IMT was observed in FED compared to controls. 
CONCLUSIONS: 
This study unequivocally shows that mutations in LCAT have a differential 
effect on preclinical atherosclerosis which appears dependent of the capacity 
of mutated LCAT to generate cholesterol esters on the atherogenic 
apolipoprotein B-containing lipoprotein fraction. While this capacity is lost in 
carriers of FLD mutations, it is unaffected in carriers of FED mutations. The 
effects on atherosclerosis in this study are unlikely to be dependent of the 
dramatic identical reduction of HDL cholesterol in both groups. 
KEYWORDS: LCAT deficiency; carotid IMT; atherosclerosis 
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INTRODUCTION 
Genetic LCAT deficiency is a rare autosomal recessive disorder due to 
mutations in the LCAT gene. Importantly, such mutations translate into two 
different clinical presentations known as familial LCAT deficiency (FLD; 
OMIM# 245900), and fish-eye disease (FED; OMIM# 136120). Compound 
heterozygosity or homozygosity is in both cases characterized by near absent 
HDL cholesterol in the circulation. 1 Heterozygosity for mutations underlying 
either FLD or FED causes up to a 40% decrease in HDL cholesterol.2, 3 In FLD 
patients, the lack of LCAT catalytic activity is complete thereby affecting the 
ability of the enzyme to esterify free cholesterol on both HDL and LDL. As a 
consequence, cholesteryl esters (CE) are virtually absent in plasma. In FED 
patients, instead, the enzyme loses its capacity to esterify cholesterol in HDL, 
but it retains the ability to esterify cholesterol on apolipoprotein (apo)B-
containing lipoproteins (VLDL and LDL). As a result, plasma CE are mainly 
associated with LDL particles.1 Clinical manifestations of a loss of LCAT activity 
are only observed in subjects who are homozygotes or compound 
heterozygotes for LCAT mutations.1  
Corneal opacity is the most common feature in FLD and FED cases whereas 
anaemia, proteinuria and renal disease are clinical features in only FLD cases.1 
Of note, glomerulosclerosis is the major cause of morbidity and mortality in 
FLD cases as it often ultimately leads to renal failure.1 The pathogenesis of 
renal disease in FLD is not completely understood, but is likely due to the 
presence in plasma of large molecular weight LDL particles 4, 5 and abnormal 
lipoproteins such as Lipoprotein X.6   
Based on the inverse association between HDL cholesterol and risk of 
cardiovascular disease (CVD) in epidemiology, 7, 8 individuals with near 
complete loss of HDL cholesterol due to loss of LCAT are hypothesized to be at 
very high CVD risk. Studies into overt and subclinical atherosclerosis of 
carriers of LCAT mutations have, however, thus far provided surprisingly 
opposing results. In a first study by Ayyobi et al., 2 homozygotes and 7 
heterozygotes from a large Canadian kindred with FLD have been followed for 
25 years, during which no vascular events were reported in any of the 
carriers aged up to 70 years.9  
Interestingly, the homozygous carriers had only minimal increases in carotid 
intima media thickness (IMT) and no plaques, while some IMT abnormalities 
were observed in four of seven heterozygotes.9 In a much larger carotid IMT 
study in The Netherlands, measurements were performed in 9 carriers of two 
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mutant LCAT alleles, 47 carriers of one mutant LCAT allele and 58 age and 
gender matched family controls. All individuals belonged to five families of 
whom the index cases all presented with FED.2 Heterozygous carriers were 
reported to have significantly increased carotid IMT compared to family 
controls and two had premature cardiovascular events.2 This population was 
re-assessed by measuring carotid artery wall thickness by 3.0-T carotid 
magnetic resonance imaging, finding that carriers of LCAT mutations had 
thicker carotid artery walls and 32% increase of plaque component compared 
to family controls.10  
In sharp contrast, a study in Italian families in which the majority of the index 
cases suffered from FLD showed significantly reduced carotid IMT in carriers 
of LCAT mutations compared to age-gender matched controls, with a 
convincing distinct gene-dose effect.3  
These contrasting findings suggest that preclinical atherosclerosis may follow 
a different course in partial LCAT deficiency (FED) versus complete LCAT 
deficiency (FLD). To test this hypothesis, we have first discriminated between 
heterozygotes that are associated with FLD and FED, which means that 
biochemical and clinical features have been carefully addressed. We 
subsequently, followed the exact same analysis protocol for the Dutch and 
Italian carotid IMT data. Our results unequivocally highlight remarkable 
discrepancies between the two LCAT disease entities.  
METHODS 
Subjects 
A total of 375 subjects were included in this study, 168 recruited from Italy, 
and 207 from the Netherlands. Among the 168 Italian subjects, 55 were 
carriers of LCAT mutations from the 13 previously identified families11 while 
113 controls were recruited among the blood donors attending the Servizio 
Immunoematologico Trasfusionale of the Niguarda Hospital in Milano. 12 From 
207 Dutch subjects, 40 were carriers of LCAT mutations and 167 were 
controls, recruited as unaffected family members from the 13 identified Dutch 
LCAT families.10 All heterozygotes for LCAT mutations were assigned to either 
FLD or FED groups on the basis of their biochemical and clinical information. 
In some cases, information on the biochemical analyses of the mutant 
recombinant LCAT proteins was used.3 In case such analyses were not 
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available or non-conclusive, the phenotype of the index cases was used as the 
lead discriminator. An overview of the LCAT mutations and associated 
biochemical phenotype is available as supplemental material (Table I in 
supplemental data). Throughout the text we refer to FLD and FED subjects as 
carriers of mutations that are associated with Familial LCAT Deficiency or Fish-
Eye Disease, respectively. A total of 16 individuals were categorized as 
homozygotes, 11 of whom were clinically diagnosed with FLD while 5 subjects 
were clinically classified as FED carriers. Of the 79 heterozygotes, 26 and 48 
subjects were classified as FLD and FED, respectively, while 5 heterozygotes 
were excluded from the analysis because their mutations could not be 
classified. 
Because of a limited number of available unaffected family members, 143 
(113 Italians and 30 Dutch) unrelated control subjects matched for age and 
gender to carriers of LCAT mutations were included in the study.  
Personal and family history of CVD and cardiovascular risk factors (smoking, 
hypertension) were surveyed by questionnaires. Biometrics including blood 
pressure were recorded. Hypertension was defined as a blood pressure over 
140/90 mm Hg or use of antihypertensive medication. None of the 
participants was taking medication known to affect plasma lipid/lipoprotein 
levels. All subjects were fully informed about the modalities, end points of the 
study and signed an informed consent. All procedures were approved by the 
institutional Ethic Committees. 
Biochemical Analysis 
Fasting blood samples were collected after an overnight fast. Plasma total 
cholesterol,            HDL-c, and triglyceride levels were determined with 
certified methods by using a Roche diagnostics Integra 400 autoanalyzer or 
Roche Cobas Mira autoanalyzer. In addition, LDL-c and non-HDL-c were 
calculated respectively by using the Friedewald’s equation and as the 
difference between total and HDL cholesterol. 
Carotid Ultrasonography 
All ultrasonographic scans were performed with the subjects laying in the 
supine position. Right and left carotid artery wall segments (common carotid 
artery, bifurcation, and the internal carotid artery) were identified according 
to specific landmarks (i.e. flow divider and crest of the bifurcation) and imaged 
over a length of 10 mm according to a ﬁxed lateral transducer angle (lateral). 
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Ultrasonographic scans were performed in a standardized fashion for carriers 
of LCAT gene mutations and controls. In both The Netherlands and Italy, the 
LCAT deficient families are living across the two Nations. All carriers and 
controls who agreed to participate in The Netherlands were asked to attend 
the Department of Vascular Medicine in Amsterdam for IMT assessment, 
whereas all carriers and controls who agreed to participate in Italy were asked 
to attend the Lipid Clinic of the Center E. Grossi Paoletti in Milan. In Italy, 
when carriers could not travel to Milan, the sonographer moved to the 
family’s site. 
In the Netherlands, an Acuson 128XP/10v (Acuson Corporation) equipped with 
a 7.0-MHz linear-array transducer was used to obtain B-mode ultrasound 
images of carotid arteries by two blinded sonographers. In Italy, ultrasound 
scanning was also performed by two blinded sonographers by using an 
ESAOTE TECHNOS machine, equipped with a multi-frequency probe of 8.5 
MHz. When one of the two sonographers moved to the family’s site around 
the country, ultrasound scanning was performed by using a portable device 
(Logiq E compact ultrasound portable system; GE) equipped with a 5.0-13.0 
MHz linear array transducer. In the Netherlands images were saved as JPEG 
image files, whereas in Italy the whole ultrasonographic scan was recorded on 
sVHS videotapes from three transducer angles (anterior, lateral and posterior). 
In order to be congruent with the Netherlands ultrasonographic protocol, only 
images from the lateral angle were considered. All IMT measurements were 
centralized in Milan and performed by a single expert reader blinded for the 
genotype of the subjects, by using dedicated software (M’Ath, Metris SRL 
France) that allows the semi-automatic edge detection of the echogenic lines 
of the intima-media complex. Whenever possible, carotid images were 
measured in at least 3 different frames. Measurements of left and right 
common carotids were averaged to calculate the mean common carotid IMT. 
Measurements of the three segments (common carotid artery, bifurcation, 
and the internal carotid artery) of left and right carotids were averaged to 
calculate the mean IMT (Average IMT); the highest IMT value among the three 
segments of the two carotids was defined as the Maximum IMT.  
Statistical Analysis 
Data were summarized as mean±SD or as mean and 95% confidence interval 
(CI) for normally distributed variables, with median and inter-quartile range
(IQR) for non-normally distributed variables and with n (%) for categorical
variables. Variables with skewed distribution were log-transformed before
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multivariable analysis. Unadjusted pairwise comparisons between groups 
were performed by Wilcoxon rank-sum test, chi-square test, or Fisher exact 
test, as indicated. 
Multivariable analysis was performed by ANCOVA using three different 
models: model 1, adjusted for age and sex; model 2, as model 1 with 
additional adjustment for BMI, smoking, hypertension, family history, total 
cholesterol, HDL-C and triglycerides. P-values below 0.05 were considered as 
significant. All tests were two-sided and were performed by SAS v. 9.4 (Sas 
Institute Inc., Cary, NC, USA). 
RESULTS 
Demographic Characteristics and Lipid Levels 
Individuals from the previously reported Italian and Dutch families with 
mutations in LCAT were combined in the current study and analysed following 
the exact same protocol. The study includes a total of 90 ascertained carriers 
of LCAT gene mutations comprising of 37 FLD and 53 FED subjects and 280 
controls. Table 1 summarizes the demographic, lifestyle and clinical 
characteristics of the included subjects. Statistical comparisons were made as 
FED vs FLD subjects, FED subjects vs controls and FLD subjects vs controls, 
respectively. 
In the current analysis, we have included homozygous or compound 
heterozygous carriers. Table II in supplemental data shows, however, that 
exclusion of these individuals accounting for possible referral bias, does not 
result in significant deviations from the first analysis. 
Amongst the 3 groups there were more male subjects in the FED group 
compared to the FLD group (P=0.066). Important for this atherosclerosis 
study, ages were very similar amongst all 3 groups. The FED group, however, 
was found to have an increased prevalence of smokers compared to FLD 
subjects (P=0.008) and controls (P=0.007). BMI and hypertension were not 
significantly different between all groups. 
With respect to lipids, total cholesterol was markedly decreased in FLD and 
FED subjects compared to controls (FED vs controls, P=0.004; FLD vs controls, 
P<0.001) but there were no statistically significant differences in total 
cholesterol between FLD and FED subjects. Interestingly, FLD subjects 
exhibited a statistically significant 20% lower LDL cholesterol compared to FED 
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subjects (P=0.04) and controls (P=0.002). However, LDL cholesterol was close 
to identical when comparing FED subjects with controls. Remarkably, 
mutations related to FLD or FED appeared to have the exact same impact on 
HDL cholesterol levels, i.e. a 42% reduction (P<0.001 for both) compared to 
controls. Non-HDL cholesterol tended to be lower in FLD subjects compared 
to controls (P=0.061) but, as for LDL cholesterol, it was identical between FED 
subjects and controls. Finally, fasting plasma triglycerides levels were 
significantly increased in FED and FLD subjects compared to controls (P=0.011 
and P<0.001, respectively). 
Carotid IMT in FLD and FED Carriers 
For the preclinical atherosclerosis studies, we compared the same 37 and 53 
carriers of LCAT mutations in FLD and FED, respectively, with 280 controls. 
Common carotid IMT values are presented using two different statistical 
adjustments as detailed in table 2. Overall, FLD subjects exhibited significantly 
lower IMT compared to FED subjects and controls among all the three carotid 
variables. Specifically, common carotid IMT was decreased in FLD subjects 
compared to FED subjects (0.59 mm (0.54-0.70) versus 0.68 (0.59-0.76), 
P=0.003). This remained highly statistically significant after correction for 
confounders (P=0.005). The decrease in common carotid IMT compared to 
controls was also significant but only after correction for confounders (0.59 
mm (0.54-0.70) versus 0.65mm (0.55-0.74), P=0.04). In sharp contrast, there 
was a significant increase in the common carotid IMT in FED compared to 
controls (P=0.009) when adjusted for age and gender. However, this statistical 
significance was lost after statistical corrections for others confounders (Table 
2). Regarding average IMT as well as maximum IMT, profound reductions 
were identified in FLD subjects compared to FED subjects (0.57 mm (0.55-
0.75) versus 0.71 mm (0.59-0.88), P<0.001) and (0.81 mm (0.67-0.90) versus 
1.16 mm (0.87-1.41), P<0.001), respectively, irrespective of statistical 
correction for confounders. The same held true for comparisons between FLD 
subjects and controls (0.57 mm (0.55-0.75) versus 0.72 mm (0.62-0.83), 
P<0.001) (0.81 mm (0.67-0.90) versus 1.12 mm (0.95-1.45), P<0.001) for 
average IMT and Maximum IMT, respectively. FED subjects were not different 
from controls for both these parameters regardless of the statistical model 
used.
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Table 1. Demographic, clinical, and lipid/lipoprotein data in carriers of LCAT mutations and controls 
 
 
FLD FED Controls 
P value 
(FED vs FLD)* 
P value 
(FED vs controls)* 
P value 
(FLD vs controls)* 
n. 37 53 280 
 
  
Gender (M, %) 21 (56.8%) 36 (67.9%) 152 (54.3%) 0.28 † 0.066 † 0.78 † 
Age (y) 42.8 ±17.8 44.4 ± 14.9 43.9 ± 13.3 0.48 0.70 0.59 
BMI (kg/m2) 24.5 ± 4.4 25.0 ± 4.2 24.9 ± 3.9 0.57 0.52 0.59 
Smoking status 
   
0.008 ‡ 0.007 ‡ 0.120 ‡ 
Never (n, %) 23(62.2%) 32(61.5%) 138(49.3%)    
Former (n, %) 11(29.7%) 5(9.6%) 82(29.3%) 
 
  
Current (n, %) 3(8.1%) 15(28.9%) 60(21.4%) 
 
  
Hypertension (n, %) 11(29.7%) 18(34.0%) 70(25.0%) 0.67 † 0.18 † 0.54 † 
Total Cholesterol 
(mg/dl) 
159.4 ± 49.8 179.7 ± 54.0 200.4 ± 38.5 0.142 0.004 <0.001 
LDL Cholesterol 
(mg/dl) 
98.4 ± 42.1 120.2 ± 47.5 122.6 ± 35.0 0.036 0.57 0.002 
HDL Cholesterol 
(mg/dl) 
33.7 ± 16.8 35.3 ± 15.5 58.2 ± 16.2 0.789 <0.001 <0.001 
Triglycerides 
 (mg/dl) 






0.111 0.01 <0.001 
Non-HDL 
Cholesterol (mg/dl) 
125.7 ± 48.9 144.3 ± 50.7 142.2 ± 39.7 0.143 0.80 0.06 
 Data are expressed as mean ± SD or as geometric mean and 95% CI or as percentage where indicated.   
* by Wilcoxon rank-sum test, except:  † chi-square test, ‡ Fisher exact test.  
171
CHAPTER 5 
     Table 2. Carotid Arteries IMT in Carriers of LCAT Gene Mutations and Controls 
FLD FED Controls 
FLD vs FED 
P values 
FLD vs controls 
P values 
FED vs controls 
P values 
Models Models Models 



























<0.001 <0.001 <0.001 <0.001 0.32 0.32 
    Data are geometric means and (95% CI) 
 Model 1: adjusted for age and gender 
 Model 2: as model 1 plus BMI, smoking, hypertension, family history, total cholesterol, HDL-C and triglycerides.
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This is the first study showing that mutations causing FLD and FED 
differentially affect preclinical atherosclerosis. Despite almost half-century 
of LCAT research and its known important function in HDL metabolism, the 
role of this enzyme in human atherogenesis still remains controversial. So 
far, opposite findings were reported with Hovingh et al. showing 
heterozygous carriers of mutations, mostly diagnosed with FED, to be 
associated with increased atherosclerosis2 whereas Calabresi et al. 
reporting carriers of LCAT mutations, mostly FLD subjects, to be associated 
with reduced carotid atherosclerosis.3 Both studies, however, did not 
appropriately account for putative differences in mutations causing either 
FLD or FED. For the current study, we have instead carefully discriminated 
between these two entities on the basis of biochemical and clinical 
features. This may be important as LCAT in FED still esterifies cholesterol on 
the atherogenic apoB fraction of lipoproteins while such activity is missing 
in FLD. This immediately reveals the complexity of LCAT deficiency 
syndromes: when studying subjects who were included through an index 
patient suffering from FED due to compound heterozygosity for LCAT 
mutations, obligate heterozygous offspring carry either an allele that 
accounts for FED or importantly an allele that accounts for FLD. This relates 
to the notion that in such a case, the clinical phenotype is related to the 
FED allele that still renders a partially active LCAT with LDL as substrate, 
causing FED but preventing formation of lipoprotein X and subsequent 
glomerular damage. The current study tested the hypothesis that mutations 
causing FLD and FED have different effects on atherosclerosis. To test this 
hypothesis, the Dutch and Italian cohorts were combined in the largest 
available cohort of LCAT mutation carriers to date and used to re-read the 
carotid IMT. Of note, homozygotes were included in the analysis to account 
for potential referral bias (the main outcomes of the study did, however, 
not change significantly upon their exclusion; Table II supplement). FLD and 
FED mutations were shown to differently affect preclinical atherosclerosis: 
The FLD group presented overall with significantly lower IMT compared to 
both the FED group and controls among all three carotid measurements 
(P<0.001). On the other hand, significant differences between the FED and 
control groups were only observed in the common carotid IMT when 
adjusted for age and gender (P=0.009). This is not in full agreement with the 
data reported previously by Hovingh et al. who showed significant carotid 
IMT differences between FED and controls after adjustments for possible 




from the study by Duivenvoorden et al.10 A possible explanation for the 
observed differences between the two studies is likely due to the control 
populations which were composed of family controls in the first cIMT study 
whereas a combination of family controls and age and gender-matched 
controls were used in the current study. 
Several cardiovascular risk factors must be considered when studying the 
differences in vascular findings between FLD and FED. Importantly, age as 
the major risk factor in IMT studies was similar across groups. Increased 
smoking status was, however, identified as a possible confounder in FED 
subjects (P<0.008 in FED vs FLD and P<0.007 in FED vs controls). After 
adjusting for confounders (including smoking), our analysis indeed shows 
loss of statistically significant difference in common carotid IMT between 
FED subjects and controls. Except for changes in specific lipid fractions, 
there were no major differences between groups in other known 
cardiovascular risk factors (i.e. BMI and hypertension). As expected, total 
cholesterol was significantly reduced in FLD and FED subjects compared to 
controls. Interestingly, the marked reduction of HDL cholesterol levels in 
both groups was identical. This suggests that HDL cholesterol levels cannot 
account for the observed differences between FLD and FED subjects. 
However, we cannot exclude that HDL subclasses or sizes of LDL and VLDL 
particles are not affected. 13 Interestingly, however, LDL cholesterol levels 
were 20% lower in FLD subjects compared to FED subjects (P=0.04). In 
absolute values, they were even lower than LDL cholesterol targets for 
optimal CVD risk prevention according to the NCEP ATPIII guidelines (<100 
mg/dl).14 In view of the established causal role of LDL cholesterol in 
atherogenesis, this may very well explain the identified differences in 
preclinical atherosclerosis between the FLD and FED groups, since we can 
assume this concerns a life-long feature. Along the same line, non-HDL 
cholesterol was reduced in FLD subjects compared to FED and controls. 
Although this did not reach statistical significance, it may deserve attention 
in the context of the suggested (causal) role of remnant cholesterol in 
cardiovascular disease.15 Interestingly, triglycerides were increased in both 
LCAT carriers compared to controls. However, although not statistically 
significantly different, levels of plasma triglycerides in FLD were more 
increased compared to FED. Such a difference might be related to an 
increased VLDL production, which would also translate into higher LDL 
cholesterol levels. Indeed, an increased VLDL production has been 
previously shown in a murine model of LCAT deficiency.16  
The current findings are of interest when looking at LCAT, HDL cholesterol 
and atherosclerosis in a broader context. Prospective studies have 
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previously assessed LCAT activity/concentration and their association with 
preclinical atherosclerosis. 17, 18 Interestingly, low LCAT plasma levels were 
not associated with neither low HDL cholesterol levels nor with increased 
atherosclerosis in the general population. These findings strongly contrast 
with our knowledge that reduced LCAT activity due to LCAT gene mutations 
have a direct large impact on HDL cholesterol. However, such a discrepancy 
may be plausibly explained by relatively large reductions of LCAT activity in 
mutation carriers, while the variation of LCAT concentration in the studied 
population was by comparison marginal.17,18 With regard to atherosclerosis, 
the prospective studies appear to reflect a similar outcome if we were to 
pool the effects seen in carriers of FLD and FED mutations in the current 
study as this would result in a nearly zero effect. On the other hand, 
population studies have also shown a strong inverse association between 
HDL cholesterol and atherosclerosis.7,8 There is, however, little if not no 
evidence that this relation has a causal basis.19  In line with the notion that 
this relation is maybe not causal, we show here that a very prominent 42% 
reduction of HDL cholesterol levels does certainly not confer a very marked 
increase of cIMT in carriers of LCAT mutations. In fact, we recapitulate that 
carriers of FLD with marked hypoalphalipoproteinemia instead appear 
significantly protected against atherosclerosis compared to controls and 
FED. Why this is case it is currently unknown but it is tempting to speculate 
that the significantly reduced LDL cholesterol levels in these individuals 
(compared to FED and controls) is related to this observation especially 
since HDL cholesterol levels are identically reduced in the FLD and FED 
groups. We can, however, not exclude that HDL of FLD carriers have 
increased atheroprotective properties20 conferred by a higher capacity of 
HDL to induce cellular cholesterol efflux,21 endothelial protection,22 and the 
protection against oxidation. However, when it comes to the anti-oxidative 
properties that are attributed to LCAT itself 23, this is unlikely to explain our 
observations. Loss of LCAT would thus mean more atherogenesis, and this 
may only be marginally true for FED subjects. However, a recent study in 
carriers of LCAT mutations showed no significant association between loss 
of LCAT activity on either apoAI- or apoB-containing particles and 
differences in lipid oxidation parameters such as PON1 and PAF-AH,24 
making highly unlikely that oxidation plays a role in the made observations. 
Taken together our data underscore for the first time that FLD and FED 
mutations have a different effect on preclinical atherosclerosis. Whereas 
carriers of FLD mutations exhibited decreased carotid atherosclerosis, 
indicating a reduced risk of cardiovascular disease, FED showed marginally 
increased atherosclerosis. These results are in agreement with recent data 
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from our two groups reporting normal flow-mediated dilation in FLD 
carriers22 but impaired arterial stiffness in FED carriers.25 In conclusion, the 
present study suggests that the impact of mutations in LCAT on preclinical 
atherosclerosis is dependent on the capacity of mutant LCAT to esterify 
cholesterol on apoB containing lipoproteins (Graphical abstract). This is 
supported by lower LDL cholesterol in carriers of FLD mutations compared 
to carriers of FED mutations. These findings may bear consequences for 
therapeutic approaches to increase LCAT activity to fight atherosclerosis. 
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ITA 83 Missense Tyr stop FLD Heterozygote 1 
ITA 91 Missense Ser Pro FLD Heterozygote 1 
ITA 141 Missense Ala Thr FED Heterozygote 1 
ITA 147 Missense Arg Trp FLD Heterozygote 6 
ITA 218 Missense Lys Asn FLD Heterozygote 4 
ITA 244 Missense Arg His FED Heterozygote 3 
ITA 274 Missense Thr Ile FLD Heterozygote 5 
ITA 309 Missense Val Met FLD Heterozygote 2 
ITA 372 Missense Leu Arg FLD Heterozygote 3 
ITA stop(nt977-981) Stop / / FLD Compound het 2 
ITA delG, stop 16 Del, stop / / FLD Compound het 2 
ITA delG,Thr13--Met Del, missense / / FED Compound het 4 
ITA 181 Missense Ser Asn FLD Compound het 1 
ITA 91/141 Missense Ser/Ala Pro/Thr FED Compound het 2 
ITA 147 Missense Arg Trp FLD Homozygote 1 
ITA 274/83 Missense/stop Thr/Tyr Ala/stop FED Compound het 1 
ITA 218 Missense Lys Asn FLD Homozygote 1 
ITA (nt977-981)/181 Stop/missense Ser Stop/Asn FLD Compound het 2 
ITA 372 Missense Leu Arg FLD Homozygote 2 




ITA 218 Missense Lys Asn FLD Homozygote 1 
ITA 277/317 Missense Asp/Val Asn/Met FED Compound het 1 
NL 10 Missense Pro Gln FED Heterozygote 6 
NL 83 Stop Tyr - Term / FLD Heterozygote 4 
NL 123 Missense Thr Ile FED Heterozygote 6 
NL 131 Missense Asn Asp FED Heterozygote 17 
NL 178 Missense Ile Thr Unknown Heterozygote 1 
NL 222 Missense Val Phe Unknown Heterozygote 1 
NL 244 Missense Arg His FLD Heterozygote 1 
NL 298 Missense Arg Cys Unknown Heterozygote 2 
NL 309 Missense Val Met Unknown Heterozygote 3 
NL 123 Missense Thr Ile FLD Homozygote 1 
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Supplemental  Table II. Demographic, clinical, and lipid/lipoprotein data in carriers of LCAT deficiency (excluding 
homozygotes) and controls.  
FLD FED Controls P (FED vs FLD)* P (FED vs controls)* P (FLD vs controls)* 
n. 26 48 280 
Gender (M/F) 13 (50%) 32 (66.7%) 152 (54.3%) 0.16 † 0.11 † 0.67 † 
Age (y) 44.9 ± 20.6 44.5 ± 13.7 43.9 ± 13.3 0.74 0.60 0.55 
BMI (kg/m2) 25 ± 4.7 25.1 ± 4.3 24.9 ± 3.9 0.96 0.39 0.75 
Smoking status 0.16 ‡ 0.005 ‡ 0.08 ‡ 
Never (n, %) 19 (73.1%) 29 (61.7%) 138 (49.3%) 
Former (n, %) 4 (15.4%) 4 (8.5%) 82 (29.3%) 
Current (n, %) 3 (11.5%) 14 (29.8%) 60 (21.4%) 
Hypertension (n, %) 7 (26.9%) 16 (33.3%) 70 (25%) 0.57 † 0.22 † 0.83 † 
Total Cholesterol (mg/dl) 168.7 ± 42.1 185.9 ± 50.9 200.4 ± 38.5 0.23 0.03 0.0009 
LDL Cholesterol (mg/dl) 100.3 ± 36.7 124.3 ± 46.6 122.6 ± 35 0.02 0.96 0.007 








0.20 0.03 0.002 
Non-HDL Cholesterol 
(mg/dl) 
126.8 ± 45.1 148 ± 49.8 142.2 ± 39.7 0.13 0.47 0.09 
Ratio LDL-C/HDL-C 2.5 (1.6-3.2) 3.5 (2.3-4.1) 2.1 (1.6-2.8) 0.01 <0.0001 0.25 
Data are expressed as mean±SD or as geometric mean and 95% CI or as percentage where indicated. * by Wilcoxon rank-sum test, 










Supplemental figure I. IMT of Carotid Arteries in Carriers of LCAT Gene 
Mutations and Controls. Common Carotid, Average IMT and maximum IMT 
values in control subjects (n=280), FED (n=53) and FLD (n=37) carriers. 
Boxes indicate the median value with the 25th and 75th percentiles; capped 
bars indicate the 10th and 90th percentiles. 
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